Estrogen Receptor Beta Agonists for Oligodendroglial Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new therapies that target oligodendroglial dysfunction, which is a cause of cognitive symptoms in Angelman syndrome and autism spectrum disorder.
Innovation Solution
Administering a non-steroidal selective estrogen receptor beta agonist to treat Angelman syndrome and autism spectrum disorder, with compounds like AC-186 showing efficacy in rescuing oligodendrocyte precursor cell proliferation and differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used to treat Angelman syndrome and autism spectrum disorder, then current treatment options are limited, but new effective therapies are needed to address oligodendroglial dysfunction
Solution Approach 1:
The patent applies parameter changes by identifying and modulating specific molecular parameters (estrogen receptor beta signaling pathway) to achieve therapeutic effects. The invention changes the biochemical parameters of oligodendroglial cell function through ERβ agonist treatment, restoring proliferation and differentiation capabilities that are impaired in Angelman syndrome and autism spectrum disorder.
Solution Approach 2:
The patent uses an intermediary mechanism by introducing estrogen receptor beta agonists as mediating substances that bridge the gap between the genetic defect (UBE3A loss) and the functional outcome (oligodendroglial dysfunction). The ERβ agonists act as intermediaries that restore normal oligodendroglial function without directly correcting the genetic mutation.
2Reliability
If oligodendroglial dysfunction is targeted for treatment, then cognitive symptoms may improve, but the complexity of targeting specific cell types increases
Solution Approach 1:
The patent applies local quality by achieving selective targeting of oligodendroglial cells through the specific action of estrogen receptor beta agonists on ERβ-expressing cells in the oligodendroglial lineage. This selective action allows the therapy to improve cognitive symptoms associated with oligodendroglial dysfunction while minimizing off-target effects, despite the complexity of delivering the drug systemically.
3Productivity
If non-steroidal selective estrogen receptor beta agonists are administered, then oligodendroglial proliferation and differentiation are rescued, but the specificity and selectivity of the compound must be precisely controlled
Solution Approach 1:
The patent applies parameter changes by establishing specific EC50 thresholds for estrogen receptor beta binding (less than 100 nM, less than 50 nM, less than 20 nM, etc.) to ensure adequate potency. These quantitative parameters allow for precise control and optimization of compound specificity and activity, enabling the rescue of oligodendroglial proliferation and differentiation with controlled pharmacological activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of non-steroidal selective estrogen receptor beta agonists, such as AC-186, effectively reduces oligodendroglial dysfunction, delays neurodevelopmental symptoms, and improves motor coordination and myelination in subjects with Angelman syndrome and autism spectrum disorder.
Implementation Method 1
administering to the subject an effective amount of a non-steroidal selective estrogen receptor beta agonist
Implementation Method 2
The non-steroidal selective estrogen receptor beta agonist has an EC50 for estrogen receptor beta of less than 100 nM
Data Source
AI summary
The present disclosure provides, for instance, a method of treating oligodendroglial dysfunction including Angelman Syndrome and autism spectrum disorder, the method comprising administering to the subject a non-steroidal selective estrogen receptor beta agonist, thereby treating the oligodendroglial dysfunction in the subject.